Orbex is a global award-winning online forex broker, fully licensed and regulated, specializing in the provision of access to the world’s biggest and most liquid financial markets. Orbex has a rich experience of ensuring superior customer service. Traders enjoy 24/5 Multilanguage support, outstanding trading conditions and personal assistance.
Since its founding in 2009, Orbex has been focusing on quality of its services and technological advancement. We were among the first in implementing of innovative trader’s dashboard, live chat, and automated trading solutions. As a part of our Customer support program, we provide enhanced security of clients’ funds and high professionalism in confidential finance matters.
Orbex understands the value of rapid decisions on fast-paced financial markets, therefore, we ensure sharp execution, sound market analysis, and profound trading education.
For our business partners, we have prepared a prime Forex IB Program, including personal business consultant, custom marketing campaigns, innovative affiliate dashboard, competitive commissions and leading reporting technology that allows having full control over your business.
Join Orbex and enjoy the new trading experience!
Currently the President & CEO of a publicly traded startup in the temporary staffing industry, specifically what we call the "On-Demand" sector. I have been in the staffing industry for approx 14 years. I started out as an Account Executive for the largest on-demand provider in the country and have been in the staffing industry ever since.
Enjoy spending time with my wife and 3 beautiful children when Im not working. Doesn't have to be anything fancy, a day at the movies or at the park works just fine for me.
After graduating cum laude with a BA in economics from Harvard, I worked in hedge funds and investment banking for ~6 years before leaving to manage my own money full time. I am a CFA charterholder and focus mostly on microcaps / event-oriented trades as that is where I think the market tends to be least efficient. I also started a website to track interesting arbitrage opportunities for individual investors (link below) - check it out!
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Principal/Chief Executive Officer, Gil Morales & Company, LLC
Mr. Morales began his investment career in 1991 as a stockbroker in the Beverly Hills branch of Merrill Lynch. In 1994 he joined PaineWebber, Inc. where he quickly achieved Chairman's Club status as a top producer. In 1997, William O'Neil personally recruited Mr. Morales to join William O'Neil + Company, Inc. where he spent the next eight years as a Vice-President, internal Portfolio Manager responsible for managing a portion of the firm's proprietary assets, and Manager of the O'Neil Institutional Services group responsible for advising over 500 of the largest and most successful institutional investors in the world, including mutual fund, pension fund, and hedge fund clients. Mr. Morales also co-authored with William J. O'Neil a book on short-selling, "How to Make Money Selling Stocks Short," published by John Wiley & Sons in 2004. In 2004, Mr. Morales was appointed Chief Market Strategist for William O'Neil + Company, Inc.
In the period from January 1, 1998 to December 31, 2005, Mr. Morales achieved in his personal account a total return of 10,904.25% as audited by Rothstein Kass & Company, a hedge fund auditing firm. Applying a standard hedge fund 2%/20% fee structure to this return would yield a pro forma return of 5,572.04%, net of fees. Mr. Morales received his B.A. in economics from Stanford University.
Dr. Chris Kacher
Portfolio Manager, Gil Morales & Company, LLC
In 1995, Dr. Kacher operated one of the first Internet-based stock advisory services. He then went on to generate strong returns for five years in a row during the 1996-2000 period before moving to cash for most of the 2000-2002 bear market, one of the worst in history. From 1996-2001, Dr. Kacher served as chief research analyst for William O'Neil + Company, the New York Stock Exchange member firm, institutional research provider, and publisher of Investor's Business Daily newspaper. During this period, William O'Neil hand-picked Dr. Kacher to manage a portion of the firm's proprietary capital, whereupon Dr. Kacher became a top internal portfolio manager at the company.
Musically gifted, Dr. Kacher was classically trained on the piano beginning at age 3, composing his first song at age 5 which he called "Night Fog," and performing as a concert pianist from ages 5 to 12 in high-profile cities in the US and Japan. Dr. Kacher received his B.S. in Chemistry and PhD in Nuclear Physics from University of California at Berkeley, where he was awarded the Berkeley Graduate Fellowship Award and the American Chemical Society award for excellence in undergraduate research. He co-discovered Element 110 on the Periodic Table of Elements and "confirmed" the existence of Element 106. Dr. Glen Seaborg, the inventor of plutonium, supervised Dr. Kacher's work as a doctoral student at UC Berkeley.
In the 1996 to 2002 period, Dr. Kacher achieved in his personal account a total return in excess of 18,000%, as verified by KPMG, the Big Four auditor.